FDA Import Refusal AEK-2943679-5/31/1 — AstraZeneca Pharmaceuticals LP
The FDA refused shipment AEK-2943679-5/31/1 from AstraZeneca Pharmaceuticals LP (United States) on Feb 27, 2023. The refused product falls under Drugs and Biologics — DAPAGLIFLOZIN (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal Details
- Date
- Feb 27, 2023
- Country
- United States
- Product Category
- Drugs and Biologics
- Product Code
- 61PCB70 DAPAGLIFLOZIN (ANTI-DIABETIC)
- Charges
- 75